Source: Eur Respir J 2011; 37: 813-822
Disease area: Pulmonary vascular diseases



Rating:

Share or cite this content

Citations should be made in the following way:
Price L.C., Montani D., Tcherakian C., Dorfmüller P., Souza R., Gambaryan N., Chaumais M-C., Shao D.M., Simonneau G., Howard L.S., Adcock I.M., Wort S.J., Humbert M., Perros F.. Dexamethasone reverses monocrotaline-induced pulmonary arterial hypertension in rats. Eur Respir J 2011; 37: 813-822

Member's Comments

No comment yet.

Related content which might interest you: Pulmonary arterial hypertension associated with fenfluramine exposure: report of 109 cases Source: Eur Respir J 2008; 31: 343-348 Year: 2008 Terguride ameliorates monocrotaline-induced pulmonary hypertension in rats Source: Eur Respir J 2011; 37: 1104-1118 Year: 2011 Improvement of exercise capacity in monocrotaline induced pulmonary hypertension by the phosphodiesterase inhibitor Vardenafil Source: Annual Congress 2006 - Signalisation in the pulmonary vasculature: new pathways and wrong signals Year: 2006 Effects of BMPR-II signal transduction in the pulmonary vascular remodeling of monocrotaline induced pulmonary hypertension in rats Source: Annual Congress 2008 - Pathophysiology of pulmonary hypertension Year: 2008 TRAM-34 ameliorates hypoxia-induced pulmonary arterial hypertension in rats Source: Annual Congress 2013 –Pulmonary circulation: animal models and experimental treatments Year: 2013 2-Methoxyestrone inhibits vascular remodeling and attenuates monocrotaline-induced pulmonary hypertension Source: Annual Congress 2008 - Pulmonary vascular biology Year: 2008 2-Ethoxyestradiol inhibits vascular and cardiac remodeling and attenuates monocrotaline-induced pulmonary hypertension Source: Annual Congress 2007 - Cellular and molecular aspects of pulmonary hypertension Year: 2007 Current medical therapies in pulmonary arterial hypertension Source: Eur Respir Mon 2012; 57: 26-41 Year: 2012 Pulmonary vascular disease: an historical perspective Source: Eur Respir Mon 2012; 57: 1-16 Year: 2012 Early atorvastatin administration suppresses the oxygen-activating ability of rat neutrophils during monocrotalinin-induced pulmonary arterial hypertension (PAH). Source: Virtual Congress 2020 – Experimental approaches to pulmonary hypertension Year: 2020 Bosentan does not improve pulmonary hypertension and lung remodeling in heart failure Source: Eur Respir J 2011; 37: 578-586 Year: 2011 Prevention and partial reversal of monocrotaline-induced pulmonary arterial hypertension (PAH) by hsp90 inhibitors Source: Annual Congress 2012 - Pulmonary circulation: basic mechanisms, animal models and experimental treatments Year: 2012 ACE2 activation improves pulmonary endothelial function and attenuates monocrotaline-induced pulmonary hypertension Source: Annual Congress 2011 - Treatment of human pulmonary hypertension Year: 2011 Inflammation in pulmonary arterial hypertension Source: Eur Respir J 2003; 22: 358-363 Year: 2003 Effects of endothelin receptor antagonist (ERA) bosentan on myocardial glucose metabolism in pulmonary arterial hypertension (PAH) and chronic thromboembolic pulmonary hypertension (CTEPH) Source: International Congress 2017 – PAH and CTEPH Year: 2017 Inhibition of the Rho-kinase attenuates hypoxia-induced angiogenesis in the pulmonary circulation Source: Annual Congress 2006 - Pulmonary circulation: inflammation and remodelling Year: 2006 Genetics of pulmonary hypertension: from bench to bedside Source: Eur Respir J 2002; 20: 741-749 Year: 2002 Pathobiology of pulmonary arterial hypertension Source: Eur Respir J 2002; 20: 1559-1572 Year: 2002 Goal-oriented treatment and combination therapy for pulmonary arterial hypertension Source: Eur Respir J 2005; 26: 858-863 Year: 2005 IL-6 receptor overexpression in pulmonary arterial smooth muscle cells in idiopathic pulmonary hypertension Source: International Congress 2015 – Pulmonary hypertension: novel insights into the biology of the disease Year: 2015